Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma.
Robert Z. Orlowski
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Cephalon; Johnson & Johnson; Millennium; Novartis; Onyx
Honoraria - Bristol-Myers Squibb; Celgene; Cephalon; Johnson & Johnson; Millennium; Novartis; Onyx
Liana Gercheva
Research Funding - Janssen Research & Development
Cathy Williams
Honoraria - MULTIPLE Myeloma Debate; Myeloma Evening Symposium; Young Haematologist Forum
Heather J Sutherland
Honoraria - Alexion Pharmaceuticals; Celgene; Janssen-Ortho; Novartis; Roche
Tadeusz Robak
Research Funding - Janssen Research & Development
Tamás Masszi
No relevant relationships to disclose
Vesselina Goranova-Marinova
No relevant relationships to disclose
Meletios A. Dimopoulos
Consultant or Advisory Role - Ortho Biotech
Honoraria - Ortho Biotech
James D. Cavenagh
Honoraria - Janssen Pharmaceuticals
Ivan Spicka
Consultant or Advisory Role - Janssen-Cilag (U)
Honoraria - Janssen-Cilag
Angelo Maiolino
No relevant relationships to disclose
Alexander Suvorov
No relevant relationships to disclose
Joan Blade
Honoraria - Janssen Research & Development
Research Funding - Janssen Research & Development
Olga S Samoilova
No relevant relationships to disclose
Helgi Van De Velde
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Rajesh Bandekar
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Britte Kranenburg
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Hong Xie
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Jean-Francois Rossi
Honoraria - Beta Innov